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ABSTRACT 
We compare here the neurodegenerative processes observed in the hippocampus of 
bitransgenic mice with chronically altered levels of CREB function. The combination 
of genome-wide transcriptional profiling of degenerating hippocampal tissue with 
microscopy analyses reveals that the sustained inhibition of CREB function in A-
CREB mice is associated with dark neuron degeneration, whereas its strong chronic 
activation in VP16-CREB mice primarily causes excitotoxic cell death and 
inflammation. Furthermore, the meta-analysis with gene expression profiles available 
in public databases identifies relevant common markers to other neurodegenerative 
processes and highlights the importance of the immune response in 
neurodegeneration. Overall, these analyses define the ultrastructural and 
transcriptional signatures associated with these two forms of hippocampal 
neurodegeneration, confirm the importance of fine-tuned regulation of CREB-
dependent gene expression for CA1 neuron survival and function, and provide novel 
insight into the role of CREB in the etiology of neurodegenerative processes. 
 
Keywords: cAMP pathway, neurodegeneration, excitotoxicity, apoptosis, 
inflammation
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INTRODUCTION 
The cAMP signaling pathway is activated in neurons in response to a wide array of 
stimuli. Synaptic activity, hormones, growth factors released during development, 
hypoxia, and stress, among other stimuli, can trigger the phosphorylation of the 
cAMP-response element binding protein (CREB), causing its activation and the 
subsequent induction of a transient wave of CREB-dependent gene expression (1). 
This activity is necessary for the survival of different neuronal subtypes both in vitro 
and in vivo (2-6). The requirement for CREB is very stringent in the peripheral 
nervous system (7), whereas in the central nervous system, most neuronal types are 
only affected when both CREB and the cAMP-response element modulator (CREM) 
are eliminated or inhibited (8-10).  
 Our previous research on bitransgenic mice expressing either a strong 
dominant negative CREB/CREM inhibitor (A-CREB) or a constitutively active 
CREB variant (VP16-CREB) revealed markedly different initial effects of repressing 
or boosting the CREB activity in neuronal gene expression and physiology. A-CREB 
reduced intrinsic excitability and impaired long-term potentiation (LTP) (10), whereas 
VP16-CREB enhanced excitability (11) and LTP (12). Strikingly, these divergent 
early effects led to apparently similar late deleterious effects, since both 
manipulations caused in the long-term a severe loss of neurons in the CA1 subfield of 
the hippocampus in a dose and time dependent manner (10, 11).  
Do both the blockade and the enhancement of CREB function trigger the same 
cell death program? Is CREB misregulation, as previously proposed (13-18), involved 
in neurodegenerative diseases? To answer these questions, we performed parallel 
histological and cell death assays as well as gene profiling in the hippocampus of A-
CREB and VP16-CREB mice. We define the ultrastructural the transcriptional 
 Misregulation of CREB function  11/2/10  
4
signatures associated with these two forms of neurodegeneration, and show that a 
sustained blockade of CREB function leads to atrophy and dark neuron degeneration, 
whereas its strong chronic activation eventually causes excitotoxic cell death and 
widespread inflammation. These two processes are associated with differential 
activation of the immune response that determines the extent of the neuronal damage. 
 
RESULTS 
Chronic inhibition of CREB function causes dark neuron degeneration 
We used electron microscopy analysis to investigate the mechanism of cell death 
underlying the shrinkage of the CA1 subfield observed in brain sections of 
bitransgenic mice expressing the strong inhibitor of the CREB family of transcription 
factors A-CREB for several weeks (10). The CA1 pyramidal cell layer of six-week 
old A-CREB mice, a time in which the loss of CA1 neurons started to become evident 
by Nissl staining, contained a large number of shrunken pyramidal cells with highly 
osmiophilic cytoplasm (Fig. 1). These heteropycnotic cells, which represented up to 
20% of the pyramidal neurons in the dorsal hippocampus of A-CREB mice (inset in 
Fig. 1B), showed apparent nuclear and cytoplasmic condensation, clumping of 
chromatin and their nuclear and plasma membranes were ruffled (Fig. 1C). Although 
most subcellular organelles appeared to be normal, some cells exhibited swelling of 
mitochondria and the Golgi network. There was no fragmentation of the nucleus or 
cytoplasm, and adjacent neurons had a normal appearance. This description fits with 
what has been referred to as dark cell or dark neuron degeneration, a form of neuronal 
death some times associated with positive TUNEL staining, a common marker of 
apoptotic cell death (19, 20). In fact, the analysis of brain sections from A-CREB 
mice revealed the presence of TUNEL positive neurons in the CA1 subfield preceding 
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the spread of cell loss in this area (Fig. 1D). At later times, when the thickness of the 
cellular layer was severely reduced and there were few cells positive for transgene 
expression, we did not observe cells positive for TUNEL staining (bottom panel). In 
agreement with these results, we also found neurons positive for active caspase-3, 
another marker of apoptotic cell death, in the sections from 6-week old A-CREB mice 
(Sup. Fig. S1A). Brain sections of A-CREB mice were also positive for a reduced-
silver staining that labels degenerating neurons (Sup. Fig. S1B). These results, 
together with the reduced excitability and impaired plasticity observed in previous 
electrophysiological analyses (10), suggest that reduced responsiveness in A-CREB 
expressing neurons may lead to the activation of an apoptotic program that eliminates 
transgene expressing cells, explaining both the shrinkage of the cellular layer at the 
CA1 subfield and the loss of transgene expression in old mice. 
Chronic enhancement of CREB function causes inflammation  
Previous studies have demonstrated that bitransgenic mice expressing a constitutively 
active CREB variant at a high level (VP16-CREBhigh) showed enhanced intrinsic 
excitability and synaptic plasticity in the hippocampus shortly after transgene 
induction (11, 12), but late spontaneous seizures and a loss of CA1 pyramidal neurons 
(11). In agreement with these results, the electron microscopy analysis of VP16-
CREBhigh mice showed that the pyramidal cell layer maintained a normal appearance 
during the first two weeks after transgene induction (Fig. 2A, F-I). However, three 
weeks after transgene induction, incipient local signs of neurodegeneration were 
observed. Infiltrated glial cells, some cell debris, and vacuolated neurons were 
observed between the cell bodies of apparently intact CA1 pyramidal neurons (Fig. 
2B, D). Six weeks after dox removal, the number of pyramidal neurons was severely 
reduced and massive astrogliosis was apparent in both the cellular and the dendritic 
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layer (Fig. 2C, E). The immunohistological analysis using antibodies against the 
astrocyte marker GFAP (Fig. 3A) and the activated microglia marker F4/80 (Fig. 3B) 
confirmed the active gliosis observed in the electron microscopy images.  
 In terms of the number and morphology of synapses in the stratum radiatum, 
we did not observe significant differences two weeks after induction in either 
inhibitory or excitatory synapses (Fig. 2F-I). However, there was a pronounced 
reduction of glutamatergic synapses in mice expressing the transgene for six weeks 
(Fig. 2M: wt: 166±4 syn/100mm3; VP16-CREBhigh: 27±2 syn/100mm3; p<0.001). At 
these late times, we also observed ultrastructural abnormalities both at postsynaptic 
and presynaptic sites. Dendritic spines appeared smaller and elongated, whereas 
axonal terminals were enlarged and contained fewer synaptic vesicles and 
mitochondria (Fig. 2J-L).  
 Although it is now believed that seizure-induced neuronal death is primarily 
morphologically necrotic, excitotoxic insults result in mixed apoptotic-necrotic 
features depending on their intensity (20, 21). Consistent with this view, we found 
cells positive for TUNEL reaction in the hippocampus of VP16-CREBhigh mice three 
weeks after induction (Fig. 2N). Brain sections obtained at either earlier (one to two 
weeks) or later (six or more weeks) times after transgene induction were negative for 
this assay. The brain sections of VP16-CREBhigh mice were also positive for silver 
staining, (Sup. Fig. S1B). Neither cell loss nor TUNEL or neurosilver positive 
neurons were observed in bitransgenic mice that expresses lower levels of VP16-
CREB protein (VP16-CREBlow), even after one year of transgene expression (results 
not shown).  
 The features of degenerating neurons in VP16-CREBhigh mice, together with 
the enhanced excitability of VP16-CREB expressing neurons and the spontaneous 
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epileptic activity (11), indicate that cellular loss in the hippocampus of these mice is 
primarily caused by excitotoxic neuronal death and includes degenerating neurons 
undergoing apoptotic cell death. Notably, the inflammatory process associated to 
strong chronic activation of the CREB pathway was absent or very minor in mice 
with reduced CREB function: GFAP immunoreactivity was stronger and more 
widespread in the hippocampus of VP16-CREBhigh mice than in A-CREB mice (Fig. 
3A), and reactive microglia was detected only in the former (Fig. 3B). These 
observations were confirmed by gene expression analysis (Figs. 4G, S3 and 
Supplemental Tables 1 and 2).  
 
Gene expression profiles of chronic inhibition or enhancement of CREB function  
To gain additional insight into the pathological processes triggered by abnormal 
activity in the CREB pathway, we investigated the gene expression profiles active 
during ongoing neurodegeneration using microarrays. RNA samples from 
bitransgenic mice at the onset of neurodegeneration (i.e., six-week old A-CREB mice 
and VP16-CREBhigh mice three weeks after transgene induction, referred to as A-
CREB and VP16-CREB late samples, respectively) were compared with those from 
their respective control littermates. For comparison purposes, we also examined 
samples obtained at earlier time points of transgene expression, in which there were 
no evident signs of neuronal death (three-week old A-CREB mice and VP16-
CREBhigh mice one week after transgene induction, referred as A-CREB early and 
VP16-CREB early, respectively).  
As expected for an activity-regulated transcription factor, CREB inhibition 
had a milder effect on basal gene expression than its overactivation both at early (51 
vs. 280 probe sets) and late times (62 vs. 1566 probe sets) of transgene expression 
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(Fig. 4A and Sup. Tables 1 and 2). We found that at early times gene downregulations 
prevailed, although not significantly, in A-CREB mice (60.8%, P = 0.32, Fisher’s 
exact test), whereas upregulations were more frequent in VP16-CREB mice (85.4%, 
P = 1.66 x 10-19). To some extent, these numbers are in agreement with the expected 
effect of a dominant negative and a constitutively active form of a transcription factor. 
In contrast, at later times, we observed a dramatic increase in the number of 
upregulated probe sets in A-CREB mice (39.2% in early samples compared to 95.2% 
in late samples, P = 4 x 10-11) and the activation of a broad genetic program (>1000 
genes) in VP16-CREB mice that included a large number of downregulated genes (41 
probe sets in early samples compared to 336 probe sets in late samples, P = 0.001). 
The differential profile of gene expression at early and late times in both mutant 
strains might be caused by the activation of secondary genetic programs and/or 
changes in the cellular composition of the hippocampus. Thus, in the case of VP16-
CREB, we found an enrichment of CREB binding sites in the promoter of upregulated 
genes at early times after transgene induction (z-test P-value: 0.01), but not at later 
time (p= 0.13). Interestingly, ~74% of the probe sets significantly altered in the A-
CREB late samples were also affected in the VP16-CREB late samples (Fig. 4B-C). 
This common list, largely made of upregulated probe sets (~96%), revealed changes 
that were in the same direction in A-CREB and VP16-CREB mice, although their 
magnitude and statistical significance were consistently larger in VP16-CREB mice 
(Fig. 4D). 
 
Differential immune response in CREB mutant strains 
Enrichment analysis for Gene Ontology (GO) terms showed that genes related with 
the immune response (complement proteins, chemokines, etc) were overrepresented 
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among the upregulated genes in both mutant strains (Sup. Fig. S2A). The GO terms 
antigen presentation (containing both MHC class I and II), production of cytokines, 
interferon and tumor necrosis factor and wounding were specifically associated to the 
VP16-CREB late samples. Because of the prominent upregulation of non-neuronal 
markers related with the immune response in the gene expression profiles of both 
mutant strains, we evaluated in greater detail the presence of infiltrated immune cells 
in hippocampal tissue by taking advantage of the publicly available gene expression 
profiles of several types of immune and glial cells (see Sup. Methods). More than 47 
% of the significantly altered probe sets in the A-CREB late samples appeared to have 
a non-hippocampal origin, and the majority of them were also upregulated in the 
VP16-CREB
high 
late samples (Fig. 4E). Although these probe sets represented a small 
proportion of the non-hippocampal probe sets in the VP16-CREB
 
late (~2 %), they 
ranked among the most prominently changed probe sets (median of the fold-change > 
7). Our meta-analysis indicated that most of the non-hippocampal probe sets in the A-
CREB late samples could be explained by the presence of macrophage-related cells 
(Fig. 4F and Sup. Fig. S3A). Interestingly, this analysis revealed three probe sets, 
corresponding to the Trat1 and Alcam genes, that were strongly upregulated in A-
CREB samples, but unaltered in VP16-CREB late samples (see Discussion). In 
contrast, the presence at late times of non-hippocampal probe sets in the hippocampus 
of VP16-CREB mice is better explained considering the summation of the molecular 
signatures of different immune cell types (Fig. 4F and Sup. Fig. S3B). This suggests 
that a more extensive and specialized immune response and stronger gliosis take place 
in the hippocampus of VP16-CREBhigh mice than in that of A-CREB mice. Both 
histological analyses presented above and qRT-PCR assays for selected genes (Fig. 
4G) are in good agreement with these observations. 
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Comparison with other neurodegenerative processes 
To gain new insight into the role of CREB in neurodegenerative processes, we 
compared the gene expression profiles observed in CREB mutants with those 
associated with different neurodegenerative conditions in which the deregulation of 
CREB activity had been previously documented or proposed. This is the case of 
Huntington’s disease (HD) (13, 14, 22), Alzheimer’s disease (AD) (15, 23), epilepsy 
(16, 24) and aging (17, 25-27). Based on some obvious similarities with a recently 
published gene profiling analysis (28), we extended our comparison to the knockout 
mouse for palmitoyl-protein thioesterase 1 (PPT1), an animal model for infantile 
Batten disease (BD). This inheritable disorder, which has not been previously 
associated to CREB misregulation, is characterized by epilepsy and retinal and 
cortical neurodegeneration (29).  
 This meta-analyses revealed limited overlap between the gene profiles of 
CREB mutants and those of AD and HD mouse models (Fig. 5A). The few genes in 
common between the AD mouse model and the CREB animals were functionally 
related with inflammatory responses (Sup. Table 3), whereas in the case of HD mouse 
models, common changes were primarily associated to the downregulation of 
neuronal genes, including some potential direct targets of CREB, such as c-fos or 
Prodynorphin (Supplemental Table 3 and results not shown). The profile of VP16-
CREB-mediated neurodegeneration showed strong correlations with infantile BD and 
the kainate model of epilepsy (Fig. 5A and Sup. Fig. S4A-C), which encourage 
further examination of the role of CREB in these pathologies. In contrast, A-CREB 
profile exhibited very little overlapping with other neurodegenerative profiles, 
suggesting that dark cell neurodegeneration is a rare in those pathological conditions, 
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whereas inflammation was much more prevalent. Interestingly, the inspection of the 
neurodegenerative markers common to several conditions revealed two significantly 
enriched pathways (P<0.05) which correspond to initial steps in the immune 
responses: the activation of the complement and coagulation cascades, and antigen 
processing and presentation (Sup. Fig. S4D). These pathways were overrepresented in 
nearly all the tested conditions, highlighting their relevance in neurodegenerative 
disorders (Fig. 5B and Sup. Table 3).  
 
DISCUSSION  
The picture that emerges from the interdisciplinary analysis of CREB mutants with a 
loss or a gain-of-function together with previous studies in CREB deficient mice 
indicates that the precise temporal control of CREB-dependent gene expression is a 
critical requirement for the viability of CA1 pyramidal neurons and that any 
imbalance in the activity of this transduction cascade can have a negative impact in 
the survival and function of these cells, likely through misregulation of their 
responsiveness to external stimuli, since the electrophysiological alterations preceded 
the onset of neurodegeneration.  
Here, we presented first the ultrastructural signature associated to 
neurodegeneration induced by chronic inhibition or activation of CREB function. 
Degenerating neurons in A-CREB mice characteristically exhibited intracellular 
inclusions, condensation of both the cytoplasm and the nucleus, and ruffling of the 
plasma membrane, while the ultrastructure of cellular organelles was largely 
preserved. There was no inflammatory response accompanying neurodegeneration, 
and as in classical apoptosis, there was minimal damage in the surrounding cells. In 
contrast, in VP16-CREB mice, we observed a strong activation of astroglia and 
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microglia as well as other ultrastructural features that suggested an excitotoxic death, 
in which cellular contents are liberated into the intercellular space damaging 
neighboring neurons and inducing an inflammatory response. In agreement with these 
scenarios, the gene profiling analysis showed that the number of markers for 
inflammation and the magnitude and significance of the changes were higher in 
VP16-CREB mice than in A-CREB mice and provided interesting cues about the 
differential evolution of both neurodegenerative processes.  
In A-CREB mice, the expression of immune response genes was restricted to 
some chemokines and components of the complement and phagocytic systems. 
Interestingly, two immune genes, Alcam (Activated leukocyte cell adhesion molecule) 
and Trat1 (T-cell receptor interacting molecule or Trim), were strongly upregulated in 
A-CREB mice and might act as negative modulators of the immune response. Alcam 
inhibits the transendothelial migration of monocytes (30), thus providing a possible 
mechanism for limiting the infiltration of immune cells from brain capillaries, 
whereas Trat1 regulates the surface transport of CTLA-4, an immunoglobulin 
receptor that dampens T-cell responses (reviewed in (31). Therefore, the increase of 
Trat1 expression in microglia might limit its activation. These molecules could 
functionally interact with other negative modulators like the anti-inflammatory 
Serping1, also called C1 inhibitor, and the autoimmunity suppressor Fc-γIIB 
(Fcgr2b), whose expression is also increased in the hippocampus of A-CREB mice 
(Sup. Table 1) and could refrain the full activation of the complement pathway and 
prevent inflammation. In the absence of an inflammatory response, the number of 
microglia cells might be so low or transient that it escaped our microscopy analysis, 
but sufficient to increase the expression of innate immune response markers detected 
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in the gene expression profile, and to clear out apoptotic cells without damaging the 
surrounding neurons (32) (Fig. 6, right). 
In the hippocampus of VP16-CREBhigh mice, Alcam and Trat1 were not 
upregulated and the strong activation of microglia (evidenced by the F4/80 marker 
and the strong up-regulation of Emr1) and the complement cascade correlated with a 
more dramatic cellular response. The over-expression of MHC class I molecules in 
pyramidal neurons of VP16-CREBhigh mice (33), maybe physiological in origin (34), 
might convert them into antigen presenting cells, fuelling the inflammatory process. 
As a result, we observed glial overactivation (evidenced by the increase in GFAP, 
aquaporin-4, and other glial markers), the infiltration of peripheral immune cells like 
T- and B-lymphocytes and dendritic cells, and the release of pro-inflammatory 
molecules (MHC class II molecules, interleukines, etc) that may work in a positive 
feed-forward manner (Fig. 6, left).  
Our characterization of CREB mutant strains suggests that the strength of 
complement activation could determine the magnitude and features of the immune 
response associated to a neurodegenerative process. The two bitransgenic lines 
described here illustrate two different faces of the immune response in the nervous 
system: full inflammatory response versus ordered cell death clearance. This view is 
supported by the EM analysis, the cell death assays and the microarray gene profiling. 
However, the precise identity of the molecular determinants that separate the role of 
the complement system in focalized cellular clearance from aggressive inflammation 
remains undetermined (35). Further use of the analytical approaches described here 
should define distinctive transcriptional signatures and provide additional clues about 
the molecular and cellular mechanisms underlying neurodegeneration and maybe 
reveal novel therapeutic targets. 
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Finally, these results highlight the perils of prolonged and/or uncontrolled 
manipulation of the CREB signaling cascade. Although CREB activity has been 
shown to be neuroprotective in several models of neuronal damage (4, 6, 36-39), it is 
essential to be careful with the duration and strength of CREB-based therapeutics. In 
the healthy brain, the phosphorylation of CREB that occurs in response to neuronal 
activity is transient and promotes the expression of specific downstream genes in a 
narrow time window. The blockade of this function has dramatic effects in neuronal 
viability, but the maintenance of strongly elevated levels of CREB activity can be 
equally devastating.  
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MATERIALS AND METHODS 
Generation and maintenance of transgenic mice 
A-CREB (10) and VP16-CREBhigh (12) mice have been described previously. Both 
strains have been backcrossed to C57BL/6J for over twenty generations. In all our 
experiments, we used littermate mice carrying either no transgene or the tTA or tetO 
transgene alone as controls. For VP16-CREBhigh mice and control littermates 
doxycyline (dox) was administrated at 40 mg/kg of food and removed to induce 
transgene expression at the indicated times before experimentation. A-CREB mice 
were raised without dox. Animal procedures were performed according to the EU and 
national guidelines for the use of laboratory animals. 
Histological techniques 
Immunohistochemistry stainings were performed as previously described (11). The 
following primary antibodies were used: α-cleaved caspase-3 antibodies (Cell 
Signalling Technology, Beverly, MA), α-VP16 (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA), α-Flag-M2, α-F4/80 and α-GFAP (Sigma Aldrich Química S.A., 
Madrid). Secondary biotinylated antibodies, streptividin-peroxidase conjugate, and 
the DAB substrate were obtained from Sigma and fluorescent secondary antibodies 
from Invitrogen (Carlsbad, CA). For TUNEL reaction, serial brain sagittal 
cryosections of 12-µm thickness were stained using the in situ Cell Death Detection 
Kit (Roche Applied Science, Barcelona, Spain). Silver staining was carried out using 
the FD NeurosilverTM kit (FD NeuroTechnologies Inc., Catonsville, MD).  
Electron microscopy 
For electron microscopy mice were anesthetized and perfused with 4% 
paraformaldehyde and 1% glutaraldehyde in 0.1 M PB (pH 7.4). Then, coronal 
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sections were cut with a thickness of 60 μm at the level of the dorsal hippocampus 
using a Leica vibration microtome. After several washes in PB, the sections were 
postfixed with osmium tetraoxide (1% in 0.1 M PB) and block-stained with uranyl 
acetate (1% in distilled water). The sections were then dehydrated in ascending series 
of ethanol to 100% followed by propylene oxide and flat-embedded on glass slides in 
Durcupan (Fluka, Barcelona). The CA1 region of the hippocampus was cut at 70-90 
nm on an ultramicrotome (Reichert Ultracut E; Leica, Austria) and collected on 200-
mesh nickel grids. Staining was performed on drops of 1% aqueous uranyl acetate 
followed by Reynolds’s lead citrate. Ultrastructural analyses were performed with a 
Jeol-1010 electron microscope. 
Microarray analysis 
For each Mouse Genome 430 2.0 gene expression array (Affymetrix, Santa Clara, 
CA), total RNA was extracted from the hippocampi of three to four mice with the 
same age, sex and genotype to produce one pooled sample. We analyzed three late A-
CREB pooled samples (six-week old mice) and three late VP16-CREB pooled 
samples (three-week off dox) with their corresponding control littermate samples (3 
pooled samples for each strain). To compare with early changes, we included two 
pooled A-CREB early samples (three-week old mice) and two pooled VP16-CREB 
early samples (one-week off dox) with their corresponding control littermate samples. 
In the case of A-CREB mice, we used the dataset GSE14320 (10). However, in the 
case of VP16-CREB mice, since earlier gene expression analyses (33) were 
performed with old MG-U74v2 setA arrays that only interrogated a third of the 
genome, we prepared new samples from bitransgenic mice and control littermates one 
week after transgene induction and hybridized them to Mouse Genome 430 2.0 
genechips. The new datasets generated in this study will be submitted to the Gene 
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Expression Omnibus (GEO) database upon manuscript acceptance. The arrays were 
hybridized, washed and screened for quality according to the manufacturer's protocol. 
The microarray data was then analyzed using GeneSpring GX 10.0 (Agilent 
Technologies, Inc., Santa Clara, CA). An RMA algorithm was used for data 
extraction. Principal component analysis revealed clustering of samples according to 
the batch of replicates; therefore normalization was conducted using the 
corresponding control samples values as reference. The filtering criteria were: signal 
intensities >20% of the maximal expression in all the samples in at least one 
condition, a fold change >1.5, and P < 0.05 in the unpaired Student’s t-test. The 
hierarchical clustering was also performed using GeneSpring software. Additional 
bioinformatics analyses and the meta-analyses to examine the presence of immune 
and glial cells markers in the gene expression profiles of CREB mutants and to 
compare with other neurodegenerative conditions are described in Sup. Methods.  
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Figure legends 
Figure 1. Death of A-CREB expressing neurons. Electron micrographs of 
pyramidal neurons in the CA1 subfield of the dorsal hippocampus of A-CREB mice. 
A. Micrographs of the CA1 subfield in a control mouse. B-C. Micrographs of the 
CA1 subfield in six-week old A-CREB mice reveal the presence of heteropycnotic 
pyramidal cells (black arrows in Panel B, quantification in bar graph inset) not 
observed in sections from control littermates. Heteropycnotic neurons showed early 
signs of apoptotic-like degeneration, consisting of cell bodies markedly reduced in 
size and increased electron density as a result of mild condensation of the nucleus and 
the cytoplasm, and morphologically injured mitochondria. The inset in panel C shows 
a higher magnification image of the convoluted nuclear membrane and the chromatin 
clumps around the inner membrane of the nucleus (white arrows). Scale: A = 20 
microns; C = 6 microns. D.  Representative images of TUNEL reaction in the 
hippocampus of six- and eight-week old A-CREB mice (AC) and control littermates 
(WT). Three control and four mutant mice (two per time point) were analyzed. Scale: 
70 μm.  
Figure 2. Death of VP16-CREB expressing neurons. A. Electron micrographs of 
pyramidal neurons in the CA1 subfield of the dorsal hippocampus of VP16-CREBhigh 
mice showing progressive neurodegeneration after transgene induction. Micrographs 
of the CA1 subfield in control littermates (A) were undistinguishable of those of 
VP16-CREBhigh one or two weeks after transgene induction. Three weeks after 
transgene induction, a number of ultrastructural changes were appreciable both in the 
cellular layer (B and D, the left inset in Panel D shows a higher magnification image 
of the framed area) and the stratum radiatum. Six weeks after transgene expression 
the disorganization of the hippocampus was evident (C) and a large number of glial 
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cells were found in the stratum radiatum and in the proximity of pyramidal cell 
bodies, in some cases, phagocytosing those cells (E). Abbreviations: sr, stratum 
radiatum; so, stratum oriens. Asterisk, glial cell process; black arrow, glial cell 
nucleus. Scale bars: A-C = 5 microns; D-E = 2 microns. F-L: Electron microscopy of 
synapses in the stratum radiatum of VP16-CREB mice. Micrographs in control 
littermates (F and H) were undistinguishable of those of VP16-CREBhigh one (results 
not shown) or two weeks after transgene induction (G and I). Both inhibitory (F-G) 
and excitatory synapses (H-I) were normal. In contrast, three weeks after transgene 
induction, a number of ultrastructural changes were appreciable in both inhibitory (J) 
and excitatory (K) synapses. Six weeks after transgene expression (L), the 
disorganization of the stratum radiatum was profound. Abbreviations: Py, pyramidal 
cell; bt, basket cell terminal; s, spine; b, button or axon terminal; Den, dendritic shaft; 
ax, axons; G, glial cell process. Scale bars : 0.5 microns. M. Quantification of the 
number of excitatory synapses at different time points after transgene induction. N. 
Representative images of TUNEL reaction (green) in the hippocampus of VP16-
CREBhigh mice and control littermates three weeks after transgene induction (n=3 for 
both genotypes).  Sections were counterstained with DAPI (blue). Scale: 50 μm.  
Figure 3. Gliosis in VP16-CREBhigh mice. A. Left, GFAP immunostaining of the 
hippocampus of VP16-CREBhigh mice expressing (On, three weeks after transgene 
induction) or not expressing the transgene (Off, animals fed with dox food). Sections 
were double stained with antibodies against GFAP (red) and VP16 (green) and 
counterstained with DAPI (blue). Right, GFAP immunostaining of the hippocampus 
of six-week old A-CREB mice. Sections were double stained with antibodies against 
GFAP (red) and Flag-M2, which recognizes A-CREB (green), and counterstained 
with DAPI (blue). The right insets show higher magnification images. At least 3 
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independent mice per condition were used in this analysis. B. Immunostaining using 
antibodies against the microglia marker F4/80 revealed the presence of reactive 
microglia only in the hippocampus of VP16-CREBhigh mice (white arrows in higher 
magnification insets), whereas A-CREB mice did not show enhanced signal for this 
marker. Three bitransgenic mice and three control littermates were used in this 
comparison. Scale bars: 140 μm.  
Figure 4. Comparison of gene expression profiles in the hippocampus of A-
CREB and VP16-CREBhigh mice. A. The percentage of upregulated (black) and 
downregulated (white) probe sets at early and late times, as well as the number of 
probe sets altered in each condition (number on the right side), is shown. B. Squared-
Euclidean hierarchical clustering of the significantly altered probe sets in both 
bitransgenic hippocampi. Red, upregulation; yellow, no change; blue, 
downregulation. C. Venn diagram presenting the total number of affected probe sets 
and the overlap in the profiles of A-CREB and VP16-CREB late samples. D. Graphs 
showing the median of the fold changes (left) as a measure of the magnitude of the 
changes, and the median of the P-values (right) as a measure of their significance. 
‘Specific’ (white bars) refers to probe sets that passed the filters in only one of the 
two bitransgenic strains, whereas ‘Common’ (gray bars) passed in both strains. E. 
Percentage of non-hippocampal probe sets (left) and median of the fold change (right) 
in either A-CREB or VP16-CREBhigh late samples (white bars), and common to both 
strains (gray bars). The number of probe sets is indicated above each bar. F. 
Percentage of non-hippocampal genes and associated cell types: macrophages and 
microglia (green), dendritic and mast cells (red), glial cells (yellow), and others 
(blue). The numbers represent the number of genes for each cell group (see Sup. Fig. 
3 for additional detail). G. qRT-PCR assays for selected genes and  comparison with 
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the fold change of the corresponding probe sets in the microarray analysis. *, P<0.05; 
**, P<0.01 Student’s t test. 
Figure 5. Meta-analysis of neuropathological models. A. Correlation analysis of 
the transcriptional alterations associated to each on of the following pathological 
conditions: mouse model of AD (Presenilin conditional double knockout), aging (24 
months old animals), kainate-induced epilepsy (10 d after injection), HD (R6/1, R6/2, 
and CHL2), Batten disease (PPT1 8 months old knockout), and A-CREB and VP16-
CREBhigh mice at late times after transgene expression. See coloring legend for 
coefficient values. The percentage of altered genes common to the late expression 
profiles of VP16-CREBhigh mice and A-CREB mice is indicated in the right table. 
‘Up’ and ‘Down’ distinguish between upregulated and downregulated genes, 
respectively. B. Significative enrichment for canonical KEGG pathways reveals the 
presence of complement and antigen presentation genes in the profiles of 
neurodegenerative models. Analysis was performed using genes present at least in 
three (>2 common, white bars) or four (>3 common, black bars) (P-value < 0.05, see 
Supplemental Materials). 
Figure 6. Bidirectional control of CA1 neuronal survival and plasticity by 
CREB. Summary of opposite and coincidental alterations detected during the 
multidisciplinary characterization of transgenic strains with regulatable enhancement 
or inhibition of CREB function (references are indicated with numbers). The bottom 
drawings show heuristic models for the cell death mechanisms activated in each 
mouse strain according to the results of the ultrastructural and transcriptional 
profiling. a (12, 33); b (12) and others; c (11) and others; d (10, 11); e (40) and others; f 
(10) and others. 
 






